ClinicalTrials.gg
RecruitingNCT05104645KAPP-IMUUpdated Sep 13, 2023

Analysis of the Psychometric Properties of Kinematic Parameters of Locomotion Measured by Inertial Units. Validation in Healthy Volunteers and Stroke Patients

An interventional study of Analysis of the walk and Analysis of the race in Cerebral Vascular Accident, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Centre Hospitalier Universitaire Dijon · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stroke by Centre Hospitalier Universitaire Dijon — 3 open to participants now, 3 under way, none of them phase 3. Stroke · Centre Hospitalier Universitaire Dijon.

Started
2021
with 1 other
No phase
7 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Stroke by Centre Hospitalier Universitaire Dijon, this one is one of 2 that started in 2021, is one of 7 with no phase, and was the 11th registered.

Stroke

8,281 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 12 studies in Stroke by Centre Hospitalier Universitaire Dijon are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stroke by Centre Hospitalier Universitaire Dijon, or all of them as a file.
02

Study summary

Stroke is the leading cause of acquired disability in adults in France, and more than 500,000 French people are currently living with the after-effects. Hemiparesis, which is a partial deficit of motor or muscular control affecting the right or left half of the body, is the most frequent motor disorder after a stroke. Currently, the management and treatment of stroke patients consists of a combination of pharmacological treatments (drugs, botulinum toxin, etc.), the fitting of devices (orthoses, etc.) and rehabilitation (physical therapy, adapted physical activity, occupational therapy, etc.). According to the French National Authority for Health, motor rehabilitation after a stroke must meet 3 criteria: early, intensive and continuous. Functional evaluations (with validated measurement scales or analysis of locomotor activities) make it possible to monitor rehabilitation and to verify that the intensity is adapted to the patient's needs. To date, technological advances have yielded numerous gait analysis devices, ranging from motion capture platforms to inertial measurement units (IMU) and the use of motion platforms with integrated sensors. Different systems embedding an IMU on the foot, for example, answer these problems of analysis of walking in real situation. The IMUs record the movements and orientation of the foot in space; the data are then processed by algorithms to recognize the walking steps and calculate the spatiotemporal locomotion parameters. Additional IMUs positioned on the body can be added to this system in order to access a more precise analysis of locomotion, in particular by calculating the movements of the various joints of the lower limb. The validation of systems integrating IMUs must be done according to a precise method widely documented by the COSMIN recommendations (COnsensus-based Standards for the selection of health Measurement INstruments). This project will be carried out in two stages, the first of which will evaluate the safety and psychometric properties of the spatiotemporal parameters of the IMU devices in healthy subjects. If these properties (safety, reproducibility and validity) are considered to be in conformity, the second phase will be initiated. These same parameters will be evaluated during the rehabilitation of a cohort of patients who have suffered a stroke.

03

Conditions studied

  • Cerebral Vascular Accident

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers:
  • Person who has given oral consent
  • man or woman 18 years or older
  • a person who is able to understand simple orders, instructions for locomotion
  • person living within a maximum radius of 50 km from the investigation site

Patients (in addition to the above):

  • persons who have had a stroke of any origin in the last 6 months
  • person included in a rehabilitation protocol

Exclusion criteria

Exclusion Criteria:

  • persons who are not affiliated to national health insurance
  • persons subject to a legal protection measure (guardianship)
  • persons who are subject to a legal protection measure
  • pregnant women
  • adult unable to express consent
  • subject with a disarticulated hip
  • Subjects with diseases or disabilities that have an impact on walking other than those related to the stroke.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Patients after a Stroke

    Other: Analysis of the walk

  • Active comparator
    Healthy Volunteering

    Other: Analysis of the walk · Other: Analysis of the race · Other: Unipodal and bipodal jumps on flat ground

Interventions

  • OtherAnalysis of the walk

    Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)

  • OtherAnalysis of the race

    Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)

  • OtherUnipodal and bipodal jumps on flat ground

    Healthy volunteers: 2 times (between 3 and 20 days apart)

06

What researchers measure

Primary outcomes

  1. Walking speed

    Time frame: Patients: Change from baseline at week 6

  2. Walking speed

    Time frame: Healthy volunteers: Change from baseline at 20 days after inclusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Nov 2025, 50 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 50 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Nov 3, 2021
StartActual
Sep 29, 2021
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05104645
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Sep 29, 2021
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Sep 13, 2023

Study contacts

Paul ORNETTI
Contact
paul.ornetti@chu-dijon.fr
03 80 29 38 72

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion